← Back to Screener
Galectin Therapeutics Inc. (GALT)
Price$2.29
Favorite Metrics
Price vs S&P 500 (26W)-61.99%
Price vs S&P 500 (4W)-28.07%
Market Capitalization$156.67M
All Metrics
Book Value / Share (Quarterly)$0.04
P/TBV (Annual)20.45x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.37
Price vs S&P 500 (YTD)-48.88%
EPS (TTM)$-0.48
10-Day Avg Trading Volume0.40M
EPS Excl Extra (TTM)$-0.48
EPS (Annual)$-0.48
ROI (Annual)-96.40%
Cash / Share (Quarterly)$0.27
ROA (Last FY)-157.87%
EBITD / Share (TTM)$-0.31
ROE (5Y Avg)-571.52%
Cash Flow / Share (Annual)$-0.37
P/B Ratio59.80x
P/B Ratio (Quarterly)46.88x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-1.87x
ROA (TTM)-214.41%
EPS Incl Extra (Annual)$-0.48
Current Ratio (Annual)2.42x
Quick Ratio (Quarterly)2.21x
3-Month Avg Trading Volume0.44M
52-Week Price Return65.94%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.17
52-Week High$7.13
EPS Excl Extra (Annual)$-0.48
Tangible BV CAGR (5Y)-3.39%
26-Week Price Return-55.10%
Quick Ratio (Annual)2.21x
13-Week Price Return-27.30%
Total Debt / Equity (Annual)11.09x
Current Ratio (Quarterly)2.42x
Enterprise Value$272.684
Book Value / Share Growth (5Y)-34.45%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.27
3-Month Return Std Dev83.65%
Net Income / Employee (TTM)$-2
ROE (Last FY)-1165.27%
Net Interest Coverage (Annual)-1.87x
EPS Basic Excl Extra (Annual)$-0.48
Total Debt / Equity (Quarterly)11.09x
EPS Incl Extra (TTM)$-0.48
ROI (TTM)-116.07%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.17
Price vs S&P 500 (52W)31.31%
Year-to-Date Return-44.95%
5-Day Price Return-7.29%
EPS Normalized (Annual)$-0.48
ROA (5Y Avg)-165.51%
Month-to-Date Return-17.92%
EBITD / Share (Annual)$-0.31
LT Debt / Equity (Annual)11.09x
ROI (5Y Avg)-357.74%
LT Debt / Equity (Quarterly)11.09x
EPS Basic Excl Extra (TTM)$-0.48
P/TBV (Quarterly)20.45x
P/B Ratio (Annual)46.88x
Book Value / Share (Annual)$0.04
Price vs S&P 500 (13W)-29.68%
Beta0.54x
Revenue / Share (TTM)$0.00
ROE (TTM)-258.62%
52-Week Low$1.21
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
GALTGalectin Therapeutics Inc. | — | — | — | — | $2.29 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Galectin Therapeutics is a clinical-stage biopharmaceutical company developing belapectin, a galectin-3 inhibitor targeting liver fibrosis, cancer, and related diseases. Preclinical studies have demonstrated belapectin's potential to reverse liver fibrosis and cirrhosis, addressing significant unmet medical needs.